Consolato M. Sergi

Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.

Survodutide (BI 456906) is an investigational once-weekly dual glucagon and Glucagon-like Peptide (GLP-1) receptor agonist being developed for obesity. In a phase 2 trial involving adults with a body mass index ≥27 kg/m2 without diabetes, participants assigned to the 4.8-mg dose achieved a mean body-weight reduction of...